|
[1] Chinese Society of Hepatology,Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):1-16.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2011,27(1):1-16.
|
|
[2]XIONG Z,BAI LQ,WANG XJ,et al.Study on the incidence and risk factors of adverse reactions of anti-tuberculosis drugs in 115 new smear positive pulmonary tuberculosis patients[J].Pract Prevent Med,2015,22(5):537-540.(in Chinese)熊姿,白丽琼,王孝君,等.115例初治涂阳肺结核患者抗结核药物不良反应发生率和影响因素研究[J].实用预防医学,2015,22(5):537-540.
|
|
[3]PAN L,JIA ZS,CHEN L,et al.Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus[J].World J Gastroenterol,2005,11(16):2518-2521.
|
|
[4]LAI RT,CHEN CW.Antituberculosis drug-induced liver damage[J].Chin J Hepatol,2011,19(8):634-636.(in Chinese)赖荣陶,陈成伟.抗结核药物所致肝损伤[J].中华肝脏病杂志,2011,19(8):634-636.
|
|
[5]MA CC,ZHAI XH,QIN LY,et al.Study on the incidence and risk factors of liver injury in Uighur tuberculosis patients[J].Chin J Dis Control Prevent,2016,20(1):17-20.(in Chinese)马晨晨,翟啸虎,秦丽岩,等.维吾尔族肺结核患者肝损害的发生率及相关因素的调查[J].中华疾病控制杂志,2016,20(1):17-20.
|
|
[6]ZHANG PY.Guidelines for the diagnosis and treatment of tuberculosis[J].Chin J Tuberc Respir Dis,2001,24(2):70-74.(in Chinese)张培元.肺结核诊断和治疗指南[J].中华结核和呼吸杂志,2001,24(2):70-74.
|
|
[7]HU Q,LIU W,SHAO H.Research advances in pharmacotherapy for drug-induced liver injury[J].Chin J Clin Pharmacol Ther,2016,21(2):231-236.(in Chinese)胡琴,刘维,邵宏.药物性肝损伤的药物治疗研究进展[J].中国临床药理学与治疗学,2016,21(2):231-236.
|
|
[8]AGA S,BAI JR,PRAMANIK S,et al.Monitoring and management of antituberculosis drug induced hepatotoxicity[J].Gastroenterology and Hepatology,2005,20(11):1745-1752.
|
|
[9]FERNANDEZ VA,SOPEFIA B,FERNANDEZ VJ,et al.The influence of risk factors on the severity of antituberculosis drug-induced hepatotoxicity[J].Tuberc Lung Dis,2004,8(12):1499-1505.
|
|
[10]NANASHIMA K,MAWATARI T,TAHARA N,et al.Genetic variants in antioxidant pathway:risk factors for hepatotoxicity in tuberculosis patients[J].Tuberculosis(Edinb),2012,92(3):253-259.
|
|
[11]ZHANG HY,CHEN BF,ZHENG RD,et al.Hepatic histopathological changes and clinical analysis of asymptomatic HBV carriers[J].Mod Med Health,2011,27(20):3054-3056.(in Chinese)张惠勇,陈碧芬,郑瑞丹,等.乙型肝炎病毒携带者的肝组织病理与临床分析[J].现代医药卫生,2011,27(20):3054-3056.
|
|
[12]PENG YC,LIN CL,KAO CH.Increased risk of liver cirrhosis fortuberculosis infection:response to Shen[J].Eur J Clin Invest,2015,45(9):1001-1002.
|
|
[13]WU LX,LIN SM,ZHANG X,et al.Dynamic changes in B7-H1expression on peripheral blood mononuclear cel s in chronic hepatitis B patients treated with entecavir[J].J Clin Hepatol,2014,30(9):929-931.(in Chinese)吴列秀,蔺淑梅,张曦,等.接受恩替卡韦治疗的慢性乙型肝炎患者外周血单个核细胞BT-H1表达的动态变化[J].临床肝胆病杂志,2014,30(9):929-931.
|
|
[14]LUO J,DU ZH,ZHOU XQ.Evaluation of curative effect of plasma exchange combined with entecavir in treatment of chronic severe hepatitis B[J].Int J Virol,2015,22(2):120-124.(in Chinese)罗君,杜宗汉,周晓晴.血浆置换联合恩替卡韦治疗慢性重型乙型病毒性肝炎的疗效观察[J].国际病毒学杂志,2015,22(2):120-124.
|
|
[15]CHANG TT,GISH RG,de MAN R,et al.A comparison of entecavir and lamivudine for HBeA g-positive chronic hepatitis B[J].N Engl J Med,2006,354(10):1001-1010.
|
|
[16]LAI CL,SHOUVAL D,LOK AS,et al.Entecavir versus lamivudine for patients with HBeA g-negative chronic hepatitis B[J].N Engl J Med,2006,354(10):1011-1020.
|
|
[17]SHANG P,XIA Y,LIU F,et al.Incidence,clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury(ATLI)in China[J].PLoS One,2011,6(7):e21836.
|
|
[18]ZHENG YX,MA SJ,TAN DM,et al.A meta-analysis of liver lesions in hepatitis B patients undergoing anti-tuberculosis therapy[J].Chin J Hepatol,2014,22(8):585-589.
|
|
[19]KAPLOWITZ N.Drug-induced liver disorders:implications for drug development and regulation[J].Drug Safety,2001,24(8):483-490.
|
DownLoad: